TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36450853
Drug: Oral 10%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral 10% dextrose
Study: 33615641
Drug: 10 mM
Normalized name: potassium 10 MMOL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mM denatonium benzoate solution (0.1 ml/kg)
Study: 35262718
Drug: Daily low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Daily low-dose aspirin (81 mg) taken at least 5 of 7 days per week for at least 80% of follow-up time
Study: 35894657
Drug: C21 (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: C21 (200 mg)
Study: 36327320
Drug: daily oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: daily oral PrEP
Study: 36327320
Drug: daily Truvada
Normalized name: Truvada
DrugBank: Emtricitabine (DB00879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: daily Truvada
Study: 32687819
Drug: Behavioral weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral weight loss intervention (health coaching phone sessions weekly for 6 months, then monthly for 18 months or until end of pregnancy)
Study: 33691499
Drug: M. vaccae
Approvals — FDA: no, EMA: no, PMDA: no
Description: M. vaccae in combination with standard care
Study: 36083814
Drug: Daily intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily intravenous infusions of ozonized saline with ozone concentration of 2.0 mg/l for 5 days followed by standard rehabilitation (n=18)
Study: 36083814
Drug: 5 ozone
Normalized name: OZONE
DrugBank: Ozone (DB12510)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 ozone therapy procedures every other day (n=16)
Study: 36083814
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group with a 10-day course of daily breathing exercises and physiotherapy for the lungs (n=17)
Study: 35534091
Drug: Capsules
Normalized name: VG capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules
Study: 35925157
Drug: PMD200 monitoring
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PMD200 monitoring with sufentanil bolus administered when NoL index > 25 for 2 min (n=24)
Study: 35925157
Drug: Standardized sufentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized sufentanil bolus administered at anesthesiologist's discretion (n=26)
Study: 32222430
Drug: Definitive thoracic
Normalized name: Thoracol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Definitive thoracic radiation therapy (RT) administered once or twice daily for LS-SCLC
Study: 32222430
Drug: Involved field
Normalized name: Field mushroom
DrugBank: Field mushroom (DB15605)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Involved field RT using conformal advanced treatment modalities to postchemotherapy volumes
Study: 32222430
Drug: Stereotactic body
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stereotactic body radiation therapy (SBRT) or conventional fractionation for stage I or II node negative disease
Study: 32222430
Drug: Thoracic RT
Normalized name: CATH,THORACIC RT ANGLE 28FR K#573048
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thoracic RT in select patients with ES-SCLC after chemotherapy treatment
Study: 34388698
Drug: Palbociclib (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palbociclib (125 mg/d on a 3 weeks on/1 week off schedule) plus letrozole (2.5 mg/d, continuous)
Study: 33801216
Drug: Wearable focal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wearable focal muscle vibration (FMV) therapy applied using a modified MyovoltTM device, 3 days a week for 4 weeks
Study: 33801216
Drug: Wearable focal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wearable focal muscle vibration (FMV) therapy
Study: 35655286
Drug: Zhizhu Kuanzhong
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zhizhu Kuanzhong Capsule (ZZKZ)
Study: 33610123
Drug: Chemotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy with concurrent cediranib, followed by maintenance cediranib (arm C)
Study: 33610123
Drug: Chemotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy with concurrent cediranib, followed by maintenance placebo (arm B)
Study: 33610123
Drug: Chemotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy with placebo throughout (arm A, reference)
Study: 32218424
Drug: Hoodia Parviflora
Normalized name: HOODIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hoodia Parviflora (H. Parviflora) at 9 mg + 200 mg of fructo‐oligosaccharides, taken twice a day for 4 weeks
Study: 35989963
Drug: Conventional rehabilitation
Normalized name: GLUTATHIONE 12.5 g in 100 mL ORAL LIQUID [K2LTS Brain Rehabilitation]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional rehabilitation + robot-assisted hand therapy (HandTutor) for 1 hour during each session, 3 h/day, 2 days/week for 5 weeks
Study: 33030570
Drug: Lipid-lowering medications
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid-lowering medications (LLMs)
Study: 32854145
Drug: Immunotherapy (BILITE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy (BILITE design)
Study: 35420710
Drug: Machine learning
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Machine learning predictive model for heavy drinking during the first month of treatment
Study: 35420710
Drug: Machine learning
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Machine learning predictive model for heavy drinking during the last month of treatment
Study: 35420710
Drug: Machine learning
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Machine learning predictive model for heavy drinking between weekly/bi-weekly sessions
Study: 32096313
Drug: RG-101 (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: RG-101 (4 mg/kg) and GSK2878175 (20 mg) for 6 weeks
Study: 32096313
Drug: RG-101 (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: RG-101 (4 mg/kg) and GSK2878175 (20 mg) for 9 weeks
Study: 32096313
Drug: RG-101 (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: RG-101 (4 mg/kg) and GSK2878175 (20 mg) for 12 weeks
Study: 32096313
Drug: GSK2878175 long-acting
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2878175 long-acting injectable at 400 mg
Study: 38756738
Drug: Smoking cessation
Normalized name: Zyban 150 MG Smoking Cessation 12 HR Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smoking cessation treatment
Study: 35467962
Drug: Breathing and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breathing and relaxation exercises performed via telerehabilitation, twice daily for 4 weeks, with one session supervised by a physiotherapist.
Study: 33940496
Drug: Hippotherapy (16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hippotherapy (16 sessions of 30 minutes, twice a week)
Study: 32634656
Drug: Modified photodynamic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified photodynamic therapy (M-PDT)
Study: 36091003
Drug: Sintilimab (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sintilimab (200 mg, intravenous drip, once every 3 weeks) combined with apatinib (250 mg, oral administration, once a day) plus capecitabine (1000 mg/m2, twice a day; after 2 weeks of oral administration, the drug was stopped for 1 week; course of treatment, 3 weeks)
Study: 33835175
Drug: E‐WORTH (5‐session
Approvals — FDA: no, EMA: no, PMDA: no
Description: E‐WORTH (5‐session culturally tailored group‐based intervention including a 1‐hour individual HIV testing and orientation session and 4 weekly 90‐minute group sessions)
Study: 33028310
Drug: Administration of
Normalized name: IV solutions used in parenteral administration of fluids, electrolytes and nutrients
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of magnesium sulfate for severe pre-eclampsia
Study: 33028310
Drug: Administration of
Normalized name: IV solutions used in parenteral administration of fluids, electrolytes and nutrients
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of anti-hypertensive drugs for severe pre-eclampsia
Study: 33028310
Drug: Awareness of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Awareness of prophylactic use of aspirin to prevent pre-eclampsia
Study: 36501186
Drug: OliPhenolia® (OliP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: OliPhenolia® (OliP) 2 × 28 mL∙d−1 for 16 days
Study: 33115894
Drug: Bright light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bright light therapy (BLT, 9000 lux, 5000 K)
Study: 33115894
Drug: Dim red
Normalized name: acid red 35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dim red light therapy (DRLT, 100 lux, 2700 K)
Study: 34391230
Drug: Lymphatic drainage
Normalized name: PEPPERMINT 13 mg in 50 mL / SAGE OIL 5.3 mg in 50 mL TOPICAL OIL [Swelling Solution - improving lymphatic drainage]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lymphatic drainage therapy (LDT) applied for 45 minutes by an experienced physical therapist.
Study: 34391230
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (CT: rest) received 45 minutes supine on the treatment table.
Study: 32239322
Drug: Pirfenidone (2400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirfenidone (2400 mg/day)
Study: 38354688
Drug: Neoadjuvant immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant immunotherapy
Study: 34425828
Drug: Breast milk
Normalized name: BREAST MILK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breast milk cell fractions (BMCFs) administered within 6 to 12 hours after birth
Study: 35411579
Drug: TBP‐PI‐HBr test
Approvals — FDA: no, EMA: no, PMDA: no
Description: TBP‐PI‐HBr test (registration tablet)
Study: 35411579
Drug: TBP‐PI‐HBr reference
Approvals — FDA: no, EMA: no, PMDA: no
Description: TBP‐PI‐HBr reference (clinical trial tablet)
Study: 35411579
Drug: TBP‐PI‐HBr test
Approvals — FDA: no, EMA: no, PMDA: no
Description: TBP‐PI‐HBr test (registration tablet) under fed conditions
Study: 35411579
Drug: TBP‐PI‐HBr test
Approvals — FDA: no, EMA: no, PMDA: no
Description: TBP‐PI‐HBr test (registration tablet) and reference (clinical trial tablet)
Study: 34655316
Drug: Paracetamol 1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol 1000 mg plus 60 mg codeine
Study: 35545724
Drug: Single-agent treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-agent treatment of physician’s choice (TPC)
Study: 35545724
Drug: Sacituzumab govitecan
Normalized name: sacituzumab govitecan
DrugBank: Sacituzumab govitecan (DB12893)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sacituzumab govitecan (SG) with prior CDK4/6 inhibitors
Study: 35545724
Drug: Single-agent treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-agent treatment of physician’s choice (TPC) with prior CDK4/6 inhibitors
Study: 35905305
Drug: Buccally absorbed
Normalized name: COLLAGEN HEMOSTAT,ABSORBABLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buccally absorbed CBD (25 mg 3 times a day if <80 kg, or 50 mg 3 times a day if >80 kg) for 14 days postoperatively
Study: 34226219
Drug: Hyperbaric oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric oxygen (HBO) plus best practice treatment
Study: 34226219
Drug: Best practice
Normalized name: calcium polycarbophil
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Best practice treatment
Study: 36063058
Drug: Conventional open
Normalized name: BOTTLE OPENER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional open surgical treatment (Group 1)
Study: 34763338
Drug: 3% Hypertonic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3% Hypertonic Saline (HS), 5 ml/kg as continuous infusion, titrated every 6 hours to achieve serum sodium <160
Study: 34763338
Drug: 20% Mannitol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20% Mannitol (MT), 1 g/kg as IV bolus, repeated every six hours
Study: 35078404
Drug: Time between
Approvals — FDA: no, EMA: no, PMDA: no
Description: Time between preparation and colonoscopy
Study: 33998168
Drug: High-density subthreshold
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-density subthreshold micropulse laser (HSML) treatment
Study: 32210537
Drug: DEX group
Approvals — FDA: no, EMA: no, PMDA: no
Description: DEX group (loading dose of DEX at 0.5 μg/kg within 10 min, followed by infusion of DEX at 0.5 μg/kg/h until the end of surgery and PCIA for 2 days with DEX plus sufentanil)
Study: 33323237
Drug: Sensor-assisted pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sensor-assisted pump therapy
Study: 33653300
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care plus medication self-management intervention
Study: 33119861
Drug: SDZ-ADL 40
Normalized name: Adlyxin
DrugBank: Lixisenatide (DB09265)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: SDZ-ADL 40 mg subcutaneous every other week from Week 0 to Week 24, continued for patients with moderate response at Week 24 (n = 159)
Study: 33523513
Drug: tildrakizumab 100
Normalized name: tildrakizumab 100 mg/mL subcutaneous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: tildrakizumab 100 mg
Study: 33523513
Drug: tildrakizumab 200
Normalized name: Tildrakizumab
DrugBank: Tildrakizumab (DB14004)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: tildrakizumab 200 mg
Study: 35691324
Drug: ChAdOx1 nCoV-19
Normalized name: ChAdOx1 nCoV-19
DrugBank: AstraZeneca COVID-19 Vaccine (DB15656)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ChAdOx1 nCoV-19 (AZD1222) vaccine, 5 × 10^10 viral particles, two doses, administered 28 days or 84 days apart.
Study: 35691324
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (capsular group B meningococcal vaccine).
Study: 35987819
Drug: Oral enteric
Normalized name: Ascriptin Enteric Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral enteric coating lactoferrin (700 mg/day for at least 28 consecutive days)
Study: 33949022
Drug: Surgery Start
Normalized name: Star Anise Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgery Start Time (SST) - Afternoon implant placement
Study: 33949022
Drug: Pre-placement ridge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-placement ridge augmentation
Study: 32268191
Drug: Fast disintegrating
Normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fast disintegrating and dissolving Aspirin® tablet (FDDT)
Study: 32268191
Drug: Regular Aspirin®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular Aspirin® tablet (RT)
Study: 35718771
Drug: Intensive blood
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive blood pressure treatment (SBP 110–120 mmHg) in SPRINT
Study: 35718771
Drug: Intensive blood
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive blood pressure treatment (SBP 120–130 mmHg) in SPRINT
Study: 35718771
Drug: Intensive blood
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive blood pressure treatment (SBP 110–120 mmHg) in ACCORD-BP
Study: 35718771
Drug: Intensive blood
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive blood pressure treatment (SBP 120–130 mmHg) in ACCORD-BP
Study: 32252803
Drug: Physical exercise
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical exercise augmented cognitive behaviour therapy
Study: 33170262
Drug: Novel cancer
Normalized name: Cancer/testis antigen 1
DrugBank: Cancer/testis antigen 1 (DB19291)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novel cancer therapies
Study: 33434615
Drug: Medications for
Normalized name: Medicated Shampoo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medications for Alcohol Use Disorder (AUD)
Study: 32591820
Drug: (lipo)glycopeptides (LGP/GPs)
Normalized name: carbetapentane citrate / guaifenesin Oral Solution [Pulmari-GP]
Approvals — FDA: no, EMA: no, PMDA: no
Description: (lipo)glycopeptides (LGP/GPs) in combination with β-lactams
Study: 36159218
Drug: Standard systemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard systemic chemotherapy
Study: 36382660
Drug: Oral +
Normalized name: Oral Film
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral + photograph counseling
Study: 34715821
Drug: Transdermal rivastigmine
Normalized name: rivastigmine Transdermal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal rivastigmine for 12 months
Study: 33256382
Drug: Hyperimmune plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperimmune plasma (250-300 ml units with neutralizing antibodies titer ≥1:160)
Study: 38049713
Drug: Goal-directed fluid
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goal-directed fluid therapy (GDFT)
Study: 34959789
Drug: 2.5 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 g/day of Neptune krill oilTM (550 mg EPA/DHA and 150 mg choline)
Study: 35536441
Drug: Chlormethine gel
Normalized name: chlormethine
DrugBank: Mechlorethamine (DB00888)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlormethine gel
Study: 35536441
Drug: Chlormethine ointment
Normalized name: chlormethine
DrugBank: Mechlorethamine (DB00888)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlormethine ointment
Study: 35416910
Drug: Edoxaban (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edoxaban (15 mg once daily)
Study: 33917587
Drug: 4-mm short
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-mm short implants
Study: 33917587
Drug: 10-mm standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-mm standard implants
Study: 33001139
Drug: Oral dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dexmedetomidine (700 mcg)
Study: 39163362
Drug: PCT-guided treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCT-guided treatment
Study: 35899204
Drug: Guided internet-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guided internet-based cognitive behavioral therapy for insomnia (iCBT-I; i-Sleep)
Study: 33069109
Drug: 4-day stimulus–response
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-day stimulus–response compatibility (SRC) approach bias modification treatment
Study: 33136517
Drug: SGLT2 Inhibition
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SGLT2 Inhibition in Combination with Loop Diuretics
Study: 35580546
Drug: 4F-PCC for
Normalized name: 4F-PCC
DrugBank: Factor IX Complex (Human) (DB11330)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4F-PCC for factor Xa inhibitors
Study: 35580546
Drug: 4F-PCC for
Normalized name: 4F-PCC
DrugBank: Factor IX Complex (Human) (DB11330)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4F-PCC for warfarin
Study: 33413599
Drug: Continuous warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous warfarin administration
Study: 33413599
Drug: Heparin bridge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin bridge therapy
Study: 32152915
Drug: Simulation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simulation of oral absorption using GastroPlus™ and dissolution data
Study: 33511988
Drug: Bright light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bright light treatment (10,000 lux for 30 min/day)
Study: 33511988
Drug: Control treatment
Normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control treatment (inactivated negative ion generator)
Study: 32236950
Drug: Chlorambucil monotherapy
Normalized name: Chlorambucil
DrugBank: Chlorambucil (DB00291)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlorambucil monotherapy
Study: 32044505
Drug: Regular therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular therapy (control group)
Study: 32028117
Drug: GA 40
Normalized name: Potiga 400mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: GA 40 mg/mL three-times-weekly (TIW)
Study: 32028117
Drug: GA 20
Normalized name: Potiga 200mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: GA 20 mg/mL once-daily (QD)
Study: 32203978
Drug: Canakinumab (50,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canakinumab (50, 150, or 300 mg) subcutaneously once every 3 months
Study: 35572837
Drug: Moxibustion instrument
Normalized name: BUTYLENE GLYCOL 0.2 g in 1 g CUTANEOUS TAPE [ShiZhenTaiYiTang Moxibustion Patch]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxibustion instrument combined with intermediate frequency electrostatic therapy
Study: 35572837
Drug: Medium-frequency treatment
Normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium-frequency treatment (Control)
Study: 36324229
Drug: Interferon β‐1a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon β‐1a (7.5‐30 μg)
Study: 36324229
Drug: Pegylated interferon
Normalized name: Pegylated interferon alfa-2a
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pegylated interferon β‐1a (31.25‐125 μg)
Study: 32095954
Drug: eHealth treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: eHealth treatment for urinary incontinence (UI)
Study: 35382796
Drug: Closed-loop insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Closed-loop insulin delivery (CamAPS FX application, Dana Diabecare RS insulin pump)
Study: 35382796
Drug: Continuous glucose
Normalized name: sub-q infusion pump w/continuous glucose monitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous glucose monitoring (CGM) with usual insulin delivery (Dexcom G6)
Study: 33551858
Drug: Control condition:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control condition: treatment as usual.
Study: 33212067
Drug: Two-dose CYD-TDV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-dose CYD-TDV regimen (0.5 mL each dose, administered subcutaneously at months 0, 6, and 12)
Study: 33212067
Drug: Three-dose CYD-TDV
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-dose CYD-TDV regimen (0.5 mL each dose, administered subcutaneously at months 0, 6, and 12)
Study: 33212067
Drug: Two-dose placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-dose placebo (administered at months 0 and 6) and one dose of CYD-TDV (administered at month 12)
Study: 32792244
Drug: SSS07, a
Approvals — FDA: no, EMA: no, PMDA: no
Description: SSS07, a humanized rabbit anti-human TNF alpha antibody
Study: 33066009
Drug: Choline supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Choline supplement (choline bitartrate, 400 mg choline/day)